Introduction: The escalation of United States (U.S.) spine surgery volume has been accompanied by considerable advancements in our understanding of spine physiology and technology. Together with implant development over the past decades, these improvements have led to shifts in implant usage. This investigation aimed to elucidate the trends in spinal implant utilization in the U.S. from 2013 to 2022.
Materials And Methods: Spine implant utilization and pricing averages between 2013 and 2022 were extracted from Orthopedic Network News. The total sample composed of 664,310 spine procedure purchase orders. Prices were adjusted for inflation based on 2022 prices. Trends were analyzed using linear regression.
Results: The U.S. spine procedure volume increased significantly from around 800,000 procedures per year in 2013 to over 1.1 million in 2022, with 73% comprising lumbar and cervical fusions. The proportion of procedures performed in patients over 64 years old increased significantly in both lumbar and cervical cases, constituting 50% and 37% of procedures, respectively. In lumbar spine in 2022, 46% of procedures utilized both pedicle screws (PSs) and interbody devices, 37% PSs only, and 13% interbody devices only. Lumbar PS price decreased significantly to $923 each despite stable lumbar and cervical fusion procedure costs. Polyetheretherketone (PEEK) and allograft interbody device usage declined while metal increased significantly.
Conclusion: Nationwide spine procedure volume rose notably from 2013 to 2022, with the majority constituting lumbar and cervical fusions. The most frequent treatment for a lumbar fusion is a PS construct with an interbody fusion device. Interbody fusion device materials witnessed decline in the use of PEEK and allograft, with metals becoming the preferred material.
Level Of Evidence: III.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11888041 | PMC |
http://dx.doi.org/10.4103/jcvjs.jcvjs_115_24 | DOI Listing |
Endokrynol Pol
March 2025
Department of Endocrine Disorders and Bone Metabolism, Chair of Endocrinology, Medical University of Lodz, Lodz, Poland.
Introduction: The authors of the latest recommendations state that osteoporosis diagnosis should not rely solely on densitometric (DXA) criteria. Fracture risk assessment is crucial for determining diagnosis and intervention thresholds. Comprehensive assessment of fracture risk requires consideration of bone mineral density (BMD) results, use of risk calculators like Fracture Risk Assessment Tool (FRAXTM), and analysis of clinical and lifestyle factors.
View Article and Find Full Text PDFEndokrynol Pol
March 2025
Department of Endocrine Disorders and Bone Metabolism, Chair of Endocrinology, Medical University of Lodz, Lodz, Poland.
Introduction: A densitometric diagnosis of osteoporosis qualifies patients to a diagnostic-therapeutic process, but densitometric evaluation may not be sufficient for osteopaenic patients. Therefore, it is essential to assess osteoporosis risk factors, fracture history, and 10-year fracture risk, and classify patients into low-, medium-, high-, or very high-risk categories. In our study, we aimed to assess the risk of fractures in patients with newly diagnosed osteopaenia and determine the percentage of patients at high and very high risk of fracture.
View Article and Find Full Text PDFJ Endocr Soc
March 2025
Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, F-59000 Lille, France.
Context: Noninvasive measurement of bone marrow adipose tissue using magnetic resonance imaging and proton density fat fraction (PDFF) may enhance clinical fractures prediction in postmenopausal women.
Objective: This study aimed to assess the association between PDFF measurements and clinical fracture incidence.
Methods: A longitudinal study was conducted.
J Integr Med
March 2025
Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences, Jinhua Academy, Zhejiang Chinese Medical University, Hangzhou Zhejiang Province, 310053, China. Electronic address:
Objective: Treating peripheral nerve injury (PNI) presents a clinical challenge due to limited axon regeneration. Strychni Semen, a traditional Chinese medicine, is clinically used for numbness and hemiplegia. However, its role in promoting functional recovery after PNI and the related mechanisms have not yet been systematically studied.
View Article and Find Full Text PDFInt J Spine Surg
March 2025
Atrium Health, Spine Center of Excellence, Charlotte, NC, USA
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!